Ghrelin receptor modulators: a patent review (2011 – 2014)

Bibliography

• Nishi Y, Yoh J, Hiejima H, Kojima M. Structures and molecular forms of the ghrelin-family peptides. Peptides 2011;32:2175-82
   PubMed Web of Science ®Google Scholar
• Al Massadi O, Tscop MH, Tong J. Ghrelin acylation and metabolic control. Peptides 2011;32:2301-8
   PubMedGoogle Scholar
• Riley LG. Different forms of ghrelin exhibit distinct biological roles in tilapia. Front Endocrinol (Lausanne) 2013;4:118
   PubMedGoogle Scholar
• Van der Lely AJ, Tshop M, Heiman ML, et al. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004;25:426-57
   PubMed Web of Science ®Google Scholar
• Ghigo E, Broglio F, Arvat E, et al. Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor. Clin Endocrinol (Oxf) 2005;62:1-17
   PubMed Web of Science ®Google Scholar
• Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005;85:495-522
   PubMed Web of Science ®Google Scholar
• Tschop M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001;50:707-9
   PubMed Web of Science ®Google Scholar
• Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001;86:5992-5
   PubMed Web of Science ®Google Scholar
• Stengel A, Tachè Y. Ghrelin: new insight to mechanisms and treatment of postoperative gastric ileus. Curr Pharm Des 2011;17:1587-93
   PubMedGoogle Scholar
• Greenwood-Van Meerveld B, Kriegsman M, Nelson R. Ghrelin as a target for gastrointestinal motility disorders. Peptides 2011;32:2352-6
   PubMedGoogle Scholar
• Mason BL, Wang Q, Zigman JM. The central nervous system sites mediating the orexigenic actions of ghrelin. Annu Rev Physiol 2014;76:519-33
   PubMed Web of Science ®Google Scholar
• Andrews ZB. Central mechanisms involved in the orexigenic actions of ghrelin. Peptides 2011;32:2248-55
   PubMed Web of Science ®Google Scholar
• Akamizu T, Kangawa K. The physiological significance and potential clinical applications of ghrelin. Eur J Intern Med 2012;23:197-202
   PubMed Web of Science ®Google Scholar
• Frago LM, Baquedano E, Argente J, et al. Neuroprotective actions of ghrelin and growth hormone secretagogues. Front Mol Neurosci 2011;4:23
   PubMed Web of Science ®Google Scholar
• Gahete MD, Cordoba-Chacon J, Kineman RD, et al. Role of ghrelin system in neuroprotection and cognitive functions: implications in Alzheimer’s disease. Peptides 2011;32:2225-8
   PubMed Web of Science ®Google Scholar
• Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001;50:1714-19
   PubMed Web of Science ®Google Scholar
• Drazen DL, Vahl TP, D’Alessio DA, et al. Effects of a fixed meal pattern on ghrelin secretion: evidence for a learned response independent of nutrient status. Endocrinology 2006;147:23-30
   PubMed Web of Science ®Google Scholar
• Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rats. Nature 2000;407:908-13
   PubMed Web of Science ®Google Scholar
• Asakawa A, Inui A, Kaga T, et al. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 2003;52:947-52
   PubMed Web of Science ®Google Scholar
• Murakami N, Hayashida T, Kuroiwa T, et al. Role for central ghrelin in food intake and secretion profile of stomach ghrelin in rats. J Endocrinol 2002;174:283-8
   PubMed Web of Science ®Google Scholar
• Lu SC, Xu J, Chinookoswong N, et al. An acyl-ghrelin-specific neutralizing antibody inhibits the acute ghrelin-mediated orexigenic effects in mice. Mol Pharmacol 2009;75:901-7
   PubMed Web of Science ®Google Scholar
• Zakhari JS, Zorrilla EP, Zhou B, et al. Oligoclonal antibody targeting ghrelin increases energy expenditure and reduces food intake in fasted mice. Mol Pharm 2012;9:281-9
   Google Scholar
• Holst B, Cygankiewicz A, Jensen TH, et al. High constitutive signaling of the ghrelin receptor. Identification of a potent inverse agonist. Mol Endocrinol 2003;17:2201-10
   PubMed Web of Science ®Google Scholar
• Holst B, Schwartz TW. Constitutive ghrelin receptor activity as a signaling set-point in appetite regulation. Trends Pharmacol Sci 2004;25:113-17
   PubMed Web of Science ®Google Scholar
• Esler WP, Rudolph J, Claus TH, et al. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology 2007;148:5175-85
   PubMed Web of Science ®Google Scholar
• Schellkens H, Dinan TG, Cryan JF, et al. Lean mean fat reducing “ghrelin” machine: hypothalamic ghrelin and ghrelin receptors as therapeutic targets in obesity. Neuropharmacology 2010;58:2-16
   PubMedGoogle Scholar
• Hassouna R, Labarthe A, Zizzari P, et al. Actions of agonists and antagonists of the ghrelin/GHS-R pathway on GH secretion, appetite, and cFos activity. Front Endocrinol 2013;4:25
   PubMedGoogle Scholar
• Costantini VJ, Vicentini E, Sabbatini FM, et al. GSK1614343, a novel ghrelin receptor antagonist, produces an unexpected increase of food intake and body weight in rodents and dogs. Neuroendocrinology 2011;94:158-68
   PubMed Web of Science ®Google Scholar
• Moulin A, Demange L, Berge G, et al. Toward potent ghrelin receptor ligands based on trisubstituted 1,2,4-triazole structure. 2. Synthesis and pharmacological in vitro and in vivo evaluations. J Med Chem 2007;50:5790-806
   PubMed Web of Science ®Google Scholar
• Moulin A, Demange L, Ryan J, et al. New trisubstituted 1,2,4-triazole derivatives as potent ghrelin receptor antagonists. 3. Synthesis and pharmacological in vitro and in vivo evaluations. J Med Chem 2008;51:689-93
   PubMed Web of Science ®Google Scholar
• Rudoph J, Esler WP, O’Connor S, et al. Quinazoline derivatives as orally available ghrelin receptor antagonists for the treatment of diabestes and obesity. J Med Chem 2007;50:5202-16
   PubMedGoogle Scholar
• Xin Z, Serby MD, Zhao H, et al. Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists. J Med Chem 2006;49:4459-69
   PubMed Web of Science ®Google Scholar
• Demange L, Boeglin D, Moulin A, et al. Synthesis and pharmacological in vitro and in vivo evaluations of novel triazole derivatives as ligands of the ghrelin receptor. 1. J Med Chem 2007;50:1939-57
   PubMed Web of Science ®Google Scholar
• Serby MD, Zhao H, Szczepankiewicz BG, et al. 2,4-Diaminopyrimidine derivatives as potent growth hormone secretagogue receptor antagonists. J Med Chem 2006;49:2568-78
   PubMed Web of Science ®Google Scholar
• McCoull W, Barton P, Broo A, et al. Identification of pyrazolo-pyrimidinones as GHS-R1a antagonists and inverse agonists for the treatment of obesity. MedChemComm 2013;4:456-62
   Google Scholar
• Sun Y, Wang P, Zheng H, Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA 2004;101:4679-84
   PubMed Web of Science ®Google Scholar
• Wortley KE, del Rincon JP, Murray JD, et al. Absence of ghrelin protects against early-onset obesity. J Clin Invest 2005;115:3573-8
   PubMed Web of Science ®Google Scholar
• Zigman JM, Nakano Y, Coppari R, et al. Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 2005;115:3564-72
   PubMed Web of Science ®Google Scholar
• Tshop M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001;50:707-9
   PubMedGoogle Scholar
• Moulin A, Brunel L, Boeglin D, et al. The 1,2,4-triazole as a scaffold for the design of ghrelin receptor ligands: development of JMV 2959, a potent antagonist. Amino Acids 2013;44:301-14
   PubMedGoogle Scholar
• Pasternak A, Goble SD, de Jesus RK, et al. Discovery and optimization of novel 4-[(aminocarbonyl)amino]-N-[4-(2-aminoethyl)phenyl]benzenesulfonamide ghrelin receptor antagonists. Bioorg Med Chem Lett 2009;19:6237-40
   PubMedGoogle Scholar
• Kung DW, Coffey SB, Jones RM, et al. Identification of spirocyclic piperidine-azetidine inverse agonists of the ghrelin receptor. Bioorg Med Chem Lett 2012;22:4281-7
   PubMedGoogle Scholar
• Muccioli G, Baragli A, Granata R, et al. Heterogeneity of ghrelin/growth hormone secretagogue receptors. Toward the understanding of the molecular identity of novel ghrelin/GHS receptors. Neuroendocrinology 2007;86:147-64
   PubMedGoogle Scholar
• Sivertsen B, Lang M, Frimurer TM, et al. Unique interaction pattern for a functionally biased ghrelin receptor agonist. J Biol Chem 2011;286:20845-60
   PubMedGoogle Scholar
• Sanger GJ. Ghrelin and motilin receptor agonists: time to introduce bias into drug design. Neurogastroenterol Motil 2014;26:149-55
   PubMed Web of Science ®Google Scholar
• Sivertsen B, Holliday N, Madsen AN, Holst B. Functionally biased signaling properties of 7TM receptors – opportunities for drug development for the ghrelin receptor. Br J Pharmacol 2013;170:1349-62
   PubMedGoogle Scholar
• Dezaki K, Sone H, Koizumi M, et al. Blockade of pancreatic islet-derived ghrelin enhances insulin secretion to prevent high-fat diet-induced glucose intolerance. Diabetes 2006;55:3486-93
   PubMed Web of Science ®Google Scholar
• Bhattacarya SK, Andrews K, Beveridge R, et al. Discovery of PF-5190457, a potent, selective, and orally bioavailable ghrelin receptor inverse agonist clinical candidate. ACS Med Chem Lett 2014;5(5):474-9
   PubMed Web of Science ®Google Scholar
• Revitsky AR, Klein LC. Role of ghrelin in drug abuse and reward-relevant behaviors: a burgeoning field and gaps in the literature. Curr Drug Abuse Rev 2013;6:231-44
   PubMedGoogle Scholar
• Egecioglu E, Jerlhag E, Salome N, et al. Ghrelin increases intake of rewarding food in rodents. Addict Biol 2010;15:304-11
   PubMed Web of Science ®Google Scholar
• Leggio L, Ferrulli A, Cardone A, et al. Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving. Addict Biol 2012;17:452-64
   PubMed Web of Science ®Google Scholar
• Suchankova P, Steensland P, Fredriksson I, et al. Ghrelin receptor (GHS-R1A) antagonism suppresses both alcohol consumption and the alcohol deprivation effect in rats following long-term voluntary alcohol consumption. PLoS One 2013;8:e71284
   PubMed Web of Science ®Google Scholar
• Bahi A, Tolle V, Fehrentz JA, et al. Ghjrelin knockout mice show decreased voluntary alcohol consumption and reduced ethanol-induced conditioned place preference. Peptides 2013;43:48-55
   PubMed Web of Science ®Google Scholar
• Barnett BP, Hwang Y, Taylor MS, et al. Glucose and weight control in mice with a designed ghrelin O-acyltransferase inhibitor. Science 2010;330:1689-92
   PubMed Web of Science ®Google Scholar
• Cassoni P, Papotti M, Ghe C, et al. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab 2001;86:1738-45
   PubMed Web of Science ®Google Scholar
• Bedendi I, Alloatti G, Marcantoni A, et al. Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin. Eur J Pharmacol 2003;476:87-95
   PubMed Web of Science ®Google Scholar
• Thompson NM, Gill DA, Davies R, et al. Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology 2004;145:234-42
   PubMed Web of Science ®Google Scholar
• Broglio F, Gottero C, Prodam F, et al. Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab 2004;89:3062-5
   PubMed Web of Science ®Google Scholar
• Heppner KM, Tong J. Regulation of glucose metabolism by the ghrelin system: multiple players and multiple actions. Eur J Endocrinol 2014;171(1):R21-32
   Web of Science ®Google Scholar
• Tong J, Davis HW, Summer S, et al. Acute administration of unacylated ghrelin has no effect on basal or stimulated insulin secretion in healthy humans. Diabetes 2014;63(7):2309-19
   PubMedGoogle Scholar
• Kirkner H, Heppner KM, Holland J, et al. Ablation of ghrelin-O-acyltransferase does not improve glucose intolerance or body adiposity in mice on a leptin-deficient ob/ob background. PLoS One 2013;22:e61822
   Google Scholar
• Larsen SB, Riber D. Ghrelin analogues. WO2013113916A2; 2013
   Google Scholar
• Bloxham J, Bradley SE, Sambrook-Smith CP, et al. Piperidine amides as modulators of the ghrelin receptor. WO2011117254A1; 2011
   Google Scholar
• Hoveyda HR, Marsault E, Gagnon R, et al. Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): development of ulimorelin (TZP-101) from hit to clinic. J Med Chem 2011;54:8305-20
   PubMed Web of Science ®Google Scholar
• Marsault E, Hoveyda HR, Peterson ML, et al. Discovery of a new class of macrocyclic antagonists to the human motilin receptor. J Med Chem 2006;49:7190-7
   PubMedGoogle Scholar
• Fraser GL, Hoveyda HR, Tannenbaum GS. Pharmacological demarcation of the growth hormone, gut motility and feeding effects of ghrelin using a novel ghrelin receptor agonist. Endocrinology 2008;149:6280-8
   PubMedGoogle Scholar
• Lasseter KC, Shaughnessy L, Cummings D, et al. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol 2008;48:193-202
   PubMed Web of Science ®Google Scholar
• Charoenthongtrakul S, Giuliana D, Longo KA, et al. Enhanced gastrointestinal motility with orally active ghrelin receptor agonists. J Pharmacol Exp Ther 2009;329:1178-86
   PubMed Web of Science ®Google Scholar
• Garcia JM, Polvino WJ. Pharmacodynamic hormonal effects of of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in human volunteers. Growth Horm IGF Res 2009;19:267-73
   PubMed Web of Science ®Google Scholar
• Datta R, Soulard C, Teillot M, et al. RM-131: a potent gastroprokinetic agent. Gastroenterology 2011;140(Suppl 1):S-25
   Google Scholar
• Pietra C, Friend J, Greenwoord-van Meerveld B. Preclinical pharmacological profile of ipamorelin a novel gastroprokinetic for intestinal dysmotility. Gastroenterology 2011;140(Suppl 1):S-285
   Google Scholar
• Ung P, Winkler DA. Tripeptide motifs in biology: targets for peptidomimetic design. J Med Chem 2011;54:111-1125
   Google Scholar
• Giordanetto F, Kihlberg J. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? J Med Chem 2014;57:278-95
   PubMed Web of Science ®Google Scholar
• Julien M, Kay RG, Delhanty PJD, et al. In vitro and in vivo stability and pharmacokinetic profile of unacylated ghrelin (UAG) analogues. Eur J Pharm Sci 2012;47:625-35
   PubMed Web of Science ®Google Scholar
• McCallum RW, Lembo A, Esfandyari T, et al. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 2013;25:e705-17
   PubMed Web of Science ®Google Scholar
• Marsault E, Thomas H, Bherer P, et al. Modified macrocyclic ghrelin receptor modulators and methods of using the same. WO2011146845A1; 2011
   Google Scholar
• Hoveyda H, Marsault E, Thomas H, et al. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same. WO2011053821A1; 2011
   Google Scholar
• Rudolph J, O’Connor S, Coish P, et al. Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake. WO2006012577A2; 2006
   Google Scholar
• Hanrahan P, Bell J, Bottomley G, et al. Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity. Bioorg Med Chem Lett 2012;22:2271-8
   PubMed Web of Science ®Google Scholar
• Bhattacharya SK, Cameron K, Fernando DP, et al. 2,3-Dihydro-1H-inden-1-yl-2,7-diazaspiro[3,6]nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor. WO2011114271; 2011
   Google Scholar
• McClure KF, Jackson M, Cameron KO, et al. Identification of potent, selective, CNS-targeted inverse agonists of the ghrelin receptor. Bioorg Med Chem Lett 2013;23:5410-14
   PubMedGoogle Scholar
• Meyer C. Final answer: ghrelin can suppress insulin secretion in humans, but is it clinically relevant? Diabetes 2010;59:2726-8
   PubMedGoogle Scholar
• Garcia RS, Pietra C, Giuliano C, et al. Asymmetric ureas and medical use thereof. WO2012113103A1; 2012
   Google Scholar
• Garcia RS, Pietra C, Giuliano C, et al. Asymmetric ureas and medical use thereof. WO2012116176A2; 2012
   Google Scholar
• Dargazanli G, Estenne-Bouhtou G, Maraboit B, et al. N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy. WO2004013101A2; 2004
   Google Scholar
• Linnanen T, Rist O, Grimstrup M, et al. Ghrelin receptor modulators. 7TM Pharma A/S. WO2008092681; 2008
   Google Scholar
• Aicher B, Muller G, Paulini K, et al. Novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors. WO2012035124A1; 2012
   Google Scholar
• Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. A randomized trial. Ann Intern Med 2008;149:601-11
   PubMed Web of Science ®Google Scholar
• Heal DJ, Gosden J, Smith SL. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br J Clin Pharmacol 2009;68:861-74
   PubMed Web of Science ®Google Scholar
• Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther 2014;95:53-66
   PubMed Web of Science ®Google Scholar
• Heal DJ, Gosden J, Smith SL. A review of late-stage CNS drug candidates for the treatment of obesity. Int J Obes (Lond) 2013;37:107-17
   PubMed Web of Science ®Google Scholar
• Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo-controlled study. Lancet 2009;374:1606-16
   PubMed Web of Science ®Google Scholar
• Alizè Pharma launches the first Phase I clinical trial for AZP-531, its unacylated ghrelin analog, in type 2 diabetes. Available from: http://www.alz-pharma.com/actualite/alize-pharma-launches-the-first-phase-i-clinical-trial-for-azp-531-its-unacylated-ghrelin-analog-in-type-2-diabetes [Last accessed 25 April 2014]
   Google Scholar
• Pfizer Portfolio. Available from: http://www.pfizer.com/partnering/areas_of_interest/our_portfolio [Last accessed 25 April 2014]
   Google Scholar
• Helsinn website: the ghrelin platform. Available from: http://www.helsinn.com/Institutional.aspx?Root=211&L2=229&L3=255&Lingua=EN [Last accessed 25 April 2014]
   Google Scholar
• Garcia JM, Polvino WJ. Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunterers. Growth Horm IGF Res 2009;19:267-73
   PubMed Web of Science ®Google Scholar
• Ankersen M. Compounds with growth hormone releasing properties. US 20010041720A1; 2001
   Google Scholar
• Helsinn website: Anamorelin. Available from: http://www.helsinn.com/Institutional.aspx?Root=212&L2=232&L3=274&L4=272&Lingua=EN [Last accessed 25 April 2014]
   Google Scholar
• Tranzyme Pharma Portfolio. Available from: http://higbio.com/portfolio/company/148 [Last accessed 25 April 2014]
   Google Scholar
• BloombergBusinnesweek. News: tranzyme skids after failure of TZP-102 study. Available from: http://www.businessweek.com/ap/2012-11-15/tranzyme-skids-after-failure-of-tzp-102-study [Last accessed 25 April 2014]
   Google Scholar
• Tranzyme Pharma announces top-line results of TZP-102 Phase 2b trial. Available from: http://ir.ocerainc.com/releasedetail.cfm?releaseid=721471 [Last accessed 25 April 2014]
   Google Scholar
• Aeterna Zentaris website: news releases: Aeterna Zentaris: New data published on its ghrelin antagonist compound, AEZS-123 (JMV2959) supports its use in alcohol addiction. Available from: http://www.aezsinc.com/en/page.php?p=60&q=323 [Last accessed 25 April 2014]
   Google Scholar
• Aeterna Zentaris submits new drug application to FDA for macmorelin acetate (AEZS-130) for evaluation of AGHD. Available from: http://newdrugapprovals.org/2013/11/06/aeterna-zentaris-submits-new-drug-application-to-fda-for-macimorelin-acetate-aezs-130-for-evaluation-of-aghd/ [Last accessed 25 April 2014]
   Google Scholar
• Costantino L, Barlocco D. Ghrelin receptor modulators and their therapeutic potential. Future Med Chem 2009;1:157-77
   PubMed Web of Science ®Google Scholar